Compare GRFS & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | SHC |
|---|---|---|
| Founded | 1940 | 2015 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | N/A | 2020 |
| Metric | GRFS | SHC |
|---|---|---|
| Price | $7.99 | $15.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $10.15 | ★ $20.33 |
| AVG Volume (30 Days) | 589.6K | ★ 3.8M |
| Earning Date | 07-28-2022 | 05-05-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $1,163,617,000.00 |
| Revenue This Year | $4.49 | $7.51 |
| Revenue Next Year | $6.42 | $6.00 |
| P/E Ratio | ★ $18.67 | $174.61 |
| Revenue Growth | N/A | ★ 5.74 |
| 52 Week Low | $7.39 | $10.80 |
| 52 Week High | $11.14 | $19.85 |
| Indicator | GRFS | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 54.39 |
| Support Level | $7.87 | $15.18 |
| Resistance Level | $9.78 | $16.48 |
| Average True Range (ATR) | 0.21 | 0.49 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 50.26 | 74.87 |
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.